Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
10M? 7M will be a stretch based on the past 3Q trend. Last Q barely hit 6M.
Regardless of the exchange or platform, IR needs to do their job and get the story out about the company.
Often these are fake bid/asks. My broker has mentioned that OTC isn’t regulated in the same way exchanges are regarding bid/asks. Mirages in the desert...
Who selected Lannett over larger competitors?
Accounting for contractual revenue should only be in force while the contract is in force with Epic. Not sure it makes sense for the recognition of this revenue at this point. I think it should have been accelerated at time contract was nullified with Epic, similar to writing off any remaining depreciation when an asset is removed from service. I’m no technical accountant, but believe the above to be right according to GAAP. Any accountants on the board that can validate?
You answered the wrong question. Why are CEOs then given stock options (common shares) if they dont have the ability to increase the stock price? This is often the majority of compensation for senior executives.
Clearly must be ridiculous then for companies to give CEOs stock options where they are incentivized to add value and drive the stock price up through execution.
No, they had an abbreviated ANDA accepted for review. This isn’t an approval.
It will be the 10K for the full year.
That is Lannett Adderall in stock ready for sale.
There’s much cheaper ways to increase market cap by $60M. Execution of their R&D pipeline will easily get them there.
Just as it has in the past, LPC is renewed at lower price points...every single time.
I’m not so sure on the $50M/year in a couple quarters. We have yet to maintain $7M/qtr, but would like to see a $10M quarter within the next year.
No, I don’t consult to the trash and waste industry.
Trash & waste sector? Awesome
Small R/S would pummel this stock and drive it back to current levels.
Crickets on the experience. That’s what I thought. It’s ok.
Completely agree. It has taken a long time to get here. Still a long way to go, but Will be interesting to see what takes place over the next year or so. I think bringing on LePree removes any sort of Sungen-like deal. Elite’s business relationships haven’t been the greatest, but not sure trying to build from scratch is a better option. We have 2 conference calls coming up this summer. If we don’t hear much from the annual call, we’ll hear more of the same after Q1 and may not know more until Nov.
Some don’t even recognize a response when it’s given to them. It’s ok.
I’ve led share repurchase programs at two different companies. Please discuss your experience.
Crickets. That’s what I thought.
Lol. I’m sorry that you have no experience with doing share repurchases and the reasons behind them. Clearly above your paygrade. The company can create a price floor with share repurchases. Welcome to reality. It can only hit the ask so many times during a single session, which does help drive the price up. The bloated float is absolutely killing the stock price and will be status quo until something is done about it.
Not even worth a response if you don’t understand the benefits of a small consistent share buyback. The CEO even said on the last call that he liked the idea, but with the CEO not even being paid in cash, probably not an option.
This is where IR & Treasury go hand-in-hand. I have experience in both.
Wonder what the deal is with ER. Surprises me when the low price point that it isn’t catching on sooner. Quality is a repeated concern on some message boards for Lannett Adderall, but these could just be a handful of loud voices.
Read my response again and try to understand it.
Sounds like those are on the grey sheets. Elite provides financial reporting updates with Q’s and K’s. Shouldn’t apply to ELTP.
Any recent insights on Adderall ER at pharmacy level?
No, not a fan of fluff PRs at all. Those are ridiculous and add no long-term benefit to the company.
The management of the outstanding shares is abysmal at best. Management will have to do something about it before going to an exchange, which means if they are avoiding a small consistent share buyback (which would stabilize the price, decrease volatility, bring in new investors and drive the share price up by creating a rising floor), they are sold on a reverse split. A very small consistent buyback portrays confidence in the company, especially with the colossal outstanding float.
What management is lacking is confidence from investors due to the consistent inability to execute the majority of their communicated plans. I think this is the partial reason why Nasrat is quiet on future plans since very little has come to fruition over the past 8 years. Why set the bar if it’s always out of reach and get blamed for it. Less accountability if you don’t set goals. Most CEOs will under promise and over deliver - it’s been the exact opposite since Nasrat started.
This is basic investor relations management. He addressed it at the last call, but is ignoring the elephant in the room.
Price also matters to investors, big and small. Price matters to investment funds to get a return on their investment. Investment funds stabilize and drive the price higher if value is perceived. Stock price matters for LPC, which Nasrat has admitted he won’t tap at these levels, but if the price is right he will. Fact is, price matters, especially for Elite. The company can do things about it, but is choosing not to and continues to maintain status quo. What Elite’s actions do say is that the company does not care about retail shareholders. This is the norm, regardless of whether you are on a large exchange or the OTC.
That was an announcement prior to Elite and Sungen dissolving the partnership. Great question for next cc is what will happen if FDA approval is granted.
I didn’t say Loxapine was with Lannett. Regardless, it’s a $5M market. Get real.
And you didn’t mention the $5M TOTAL market either. Elite can barely penetrate a 1.2 Billion market. Not sure a $5M market with a go-to manufacturer is going to fare any better.
Reports due? As in 10K at end of June? Expect more of the same, if not a continuation of the downwards trend in sales seen over the past couple quarters sequentially.
Funny to think that both LCI would be rewarded buy buying Elite on the cheap by not performing well with CNS drugs. Who else would be? Nasrat. Price stays depressed and he’s diluting the stock with every single paycheck. Funny how these 2 parties’ goals may not align with retail shareholders goals.
LCI CNS revenue keeps rising and has been inversely related to Elite’s revenue over the past couple quarters.
They might make it to $7M rev per quarter if they go that route. Maybe even peak at $8M when loading up pharmacies. :)
They haven’t disclosed otherwise, so yes, until we hear otherwise.
Elite is already in ~$2B market with Adderall ER & IR. How many more zeros in a total market does Elite need before they can move the needle instead of the goal post?
And yet we have no idea if they are moving forward with it or what kind of testing is being done so a multi-billion dollar market doesn’t mean much when you’re looking at it from the sidelines.
They Simply dropped the leading zero after the decimal.
For growth stocks it is measured Q to Q as well as Q/Q. This shows momentum and penetration of sales within a market. This is why Elite called out Q to Q growth when they had it and hasn’t the past couple of quarters. Their IR messaging is consistently inconsistent.
Maybe, just maybe, the bloated and excessive float has a large part in the stock price going nowhere.
You mean the shelved product that the FDA rejected? Oh yeah, that one. That’s the one that doesn’t work with the apple sauce as Nasrat hoped. The one he still hopes will be of value to some company, some day.